COPD is not a single disease. It’s an umbrella term covering several conditions that block airflow and make breathing progressively harder. The two main types are chronic bronchitis and emphysema, but most people with COPD have features of both, and doctors now recognize several additional subtypes that affect how the disease behaves and how it responds to treatment. COPD is the fourth leading cause of death worldwide, responsible for 3.5 million deaths in 2021.
Chronic Bronchitis
Chronic bronchitis is defined by a persistent cough that produces mucus on most days for at least three months in two consecutive years. The problem centers on the airways themselves. The lining of the bronchial tubes becomes inflamed and swollen, and the mucus-producing cells multiply far beyond their normal numbers. This combination narrows the air passages and traps mucus inside them, making every breath feel like it’s working against resistance.
Under a microscope, the airways of someone with chronic bronchitis show a distinctive pattern of damage: linear depressions, deep furrows, and small pouch-like outgrowths in the airway walls. Inflammatory cells infiltrate both the inner lining and the deeper tissue beneath it. The result is airways that are structurally distorted, chronically inflamed, and clogged with mucus. People with this type of COPD tend to have a productive cough as their most noticeable symptom, along with frequent chest infections and episodes where symptoms suddenly flare.
Emphysema
Emphysema attacks a different part of the lungs. Instead of the airways, the damage happens in the tiny air sacs (alveoli) at the very end of the breathing passages, where oxygen actually enters the bloodstream. These delicate sacs lose their structure and merge into larger, less efficient spaces. The lungs lose their natural elasticity, so stale air gets trapped inside and fresh air can’t get in effectively.
The primary symptom is shortness of breath, which starts during physical activity and eventually occurs even at rest. People with emphysema-dominant COPD may not cough much or produce significant mucus, but they struggle increasingly with the sensation of not getting enough air. Because the damage is to the gas-exchange surfaces rather than the airways, emphysema tends to reduce the lungs’ ability to transfer oxygen into the blood, a measurement doctors call diffusion capacity.
Most people diagnosed with COPD have some degree of both chronic bronchitis and emphysema. The balance between the two varies from person to person, and this mix influences which symptoms dominate, how fast the disease progresses, and which treatments work best.
Alpha-1 Antitrypsin Deficiency COPD
A small but important subset of COPD is genetic. Alpha-1 antitrypsin deficiency is an inherited condition affecting roughly 1 in 1,500 to 3,500 people of European descent, though it’s much rarer in people of Asian ancestry. It causes COPD through a completely different mechanism than smoking.
Normally, the body produces a protective protein that keeps a powerful immune enzyme in check. This enzyme is released by white blood cells to fight infections, but when it isn’t properly controlled, it starts destroying healthy lung tissue, particularly the alveoli. People with alpha-1 antitrypsin deficiency either don’t produce enough of this protective protein or produce a version that doesn’t work properly. The result is emphysema that develops unusually early, typically between ages 25 and 50, often in people who have never smoked or smoked only lightly. If you’re diagnosed with COPD before age 50 or have a family history of early-onset lung disease, testing for this genetic condition is important because treatment options differ.
Asthma-COPD Overlap
Some people show features of both asthma and COPD that don’t fit neatly into either category. This is called asthma-COPD overlap, or ACO. There’s no single agreed-upon definition, but the typical profile includes persistent airflow limitation (the hallmark of COPD) combined with significant reversibility when given a bronchodilator and a history of asthma or allergies, often dating to childhood. A smoking history of ten or more pack-years is also common.
A plausible path to ACO involves someone who had childhood allergies and asthma, then was exposed to years of cigarette smoke or air pollution as an adult. The combination of pre-existing airway sensitivity and ongoing damage creates a hybrid condition. What makes ACO clinically significant is that people with it tend to fare worse than those with either asthma or COPD alone. They experience more frequent and severe flare-ups, a greater burden of daily symptoms, and a lower quality of life overall.
Eosinophilic COPD
Doctors increasingly classify COPD by the type of inflammation driving it, not just the location of damage. One important subtype is eosinophilic COPD, identified by elevated levels of eosinophils, a type of white blood cell associated with allergic and inflammatory responses.
When blood eosinophil counts reach 300 cells per microliter or higher, international guidelines recommend a different treatment approach that includes inhaled corticosteroids, which are less effective in people with lower counts. This distinction matters because using eosinophil levels to guide corticosteroid treatment has been shown to reduce flare-ups by as much as 62% in clinical studies. Not everyone with COPD benefits from steroids, but people with this inflammatory profile respond markedly better. Your doctor can check your eosinophil level with a routine blood test.
COPD With Bronchiectasis
About 30% of people with COPD also have bronchiectasis, a condition where the airways become permanently widened and scarred. The two diseases share symptoms like chronic cough, mucus production, and recurring infections, which means bronchiectasis in a COPD patient can easily go unrecognized. Diagnosis requires a CT scan of the chest.
When both conditions are present, the combination is more dangerous than either alone. People with overlapping COPD and bronchiectasis have worse lung function, more frequent exacerbations, and a higher risk of death over four years compared to those with COPD alone. The widened, damaged airways become a breeding ground for bacteria, creating a cycle of infection and inflammation that accelerates lung damage. This overlap also raises the risk of pulmonary hypertension, where blood pressure in the vessels supplying the lungs climbs to harmful levels.
Biomass Smoke COPD
COPD is often thought of as a smoker’s disease, but millions of cases worldwide are caused by breathing in smoke from wood, animal dung, crop residue, or coal burned for cooking and heating. This form of COPD behaves differently from tobacco-related COPD in important ways.
People with biomass-related COPD tend to have milder airflow obstruction and better oxygen transfer in their lungs, but more scarring (fibrosis) and a distinctive pattern of air trapping. They develop less emphysema than cigarette smokers do. The reason likely comes down to physics: cigarette smoke particles penetrate much deeper into the lungs, with nearly 58% of inhaled particles depositing in the lower airways compared to about 37% for biomass smoke. The daily dose of deposited particles from cigarettes is also roughly 100 times higher. So cigarette smoke concentrates its damage in the deep lung where emphysema develops, while biomass smoke causes more airway-level inflammation and scarring.
Early-Onset COPD
COPD diagnosed before age 50 represents a distinct category that often has different root causes than the typical smoking-related disease seen in older adults. Childhood respiratory infections, underdeveloped lungs from premature birth or poor nutrition, and genetic factors like alpha-1 antitrypsin deficiency all contribute. Some people never reach full lung capacity during their growth years, meaning they start adulthood with less reserve and can develop obstructive disease with relatively little additional exposure to risk factors. Early-onset COPD tends to progress faster over a lifetime simply because the lungs have more years of decline ahead, making early detection and management especially valuable.